Royal Bank Of Canada Issues Positive Forecast for McKesson (NYSE:MCK) Stock Price

McKesson (NYSE:MCK) had its price target upped by Royal Bank Of Canada from $845.00 to $965.00 in a report published on Thursday,Benzinga reports. The firm currently has a sector perform rating on the stock.

A number of other equities analysts also recently issued reports on MCK. TD Cowen upped their price target on McKesson from $989.00 to $1,006.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Leerink Partners increased their price target on shares of McKesson from $1,030.00 to $1,070.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 7th. Robert W. Baird set a $1,015.00 price target on shares of McKesson in a research note on Thursday, August 6th. Bank of America lifted their price objective on shares of McKesson from $950.00 to $1,050.00 in a research note on Thursday, August 6th. Finally, UBS Group increased their price objective on McKesson from $1,080.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Friday, October 16th. Fifteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,023.24.

McKesson Stock Performance

Shares of MCK stock opened at $1,075.38 on Thursday. The company has a 50 day moving average price of $934.72 and a 200 day moving average price of $866.92. The stock has a market capitalization of $125.38 billion, a P/E ratio of 27.65, a price-to-earnings-growth ratio of 2.13 and a beta of 0.27. McKesson has a fifty-two week low of $723.68 and a fifty-two week high of $1,121.50.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, November 4th. The company reported $11.68 earnings per share for the quarter, topping analysts’ consensus estimates of $10.72 by $0.96. McKesson had a net margin of 1.12% and a negative return on equity of 235.48%. The firm had revenue of $110.96 billion for the quarter, compared to analyst estimates of $109.90 billion. During the same period in the prior year, the firm earned $9.86 earnings per share. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. On average, research analysts forecast that McKesson will post 44.71 EPS for the current fiscal year.

McKesson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, January 4th. Shareholders of record on Tuesday, December 1st will be given a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, December 1st. This represents a $3.76 annualized dividend and a yield of 0.3%. McKesson’s dividend payout ratio (DPR) is presently 9.67%.

Insider Activity at McKesson

In related news, EVP Francisco Fraga sold 600 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $1,050.00, for a total transaction of $630,000.00. Following the sale, the executive vice president owned 5,064 shares in the company, valued at approximately $5,317,200. This trade represents a 10.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total value of $98,950.95. Following the transaction, the chief accounting officer owned 521 shares in the company, valued at $464,445.45. This trade represents a 17.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,812 shares of company stock valued at $1,794,182 over the last quarter. Insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Nvwm LLC raised its holdings in McKesson by 933.3% in the third quarter. Nvwm LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 28 shares during the period. Delos Wealth Advisors LLC acquired a new position in McKesson in the second quarter valued at about $27,000. Trellis Wealth Advisors LLC acquired a new position in shares of McKesson in the 3rd quarter valued at approximately $32,000. GK Wealth Management LLC acquired a new position in shares of McKesson in the third quarter valued at approximately $38,000. Finally, Curry Webb Wealth Management LLC acquired a new stake in shares of McKesson in the 3rd quarter valued at about $38,000. 85.07% of the stock is owned by hedge funds and other institutional investors.

Key McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: For fiscal Q2 2027, McKesson reported adjusted EPS of $11.68 versus analyst estimates near $10.70, while revenue of about $111 billion also topped expectations and grew roughly 7.5% year over year. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40, citing specialty-drug demand, higher prescription volumes, operating improvements and GLP-1 momentum. The company also completed its $2.25 billion Precision Medicine Group acquisition, expanding its healthcare services footprint. Earnings Call Highlights: Raised Guidance, GLP-1 Momentum
• Positive Sentiment: Several firms raised targets, including TD Cowen, Leerink Partners and Evercore ISI to $1,200; Deutsche Bank raised its target to $1,120. RBC also praised McKesson’s execution, and a Seeking Alpha analysis described normalized earnings as supporting an attractive valuation. TD Cowen Raises Price Target
• Neutral Sentiment: EVP Francisco Fraga sold 600 shares under a pre-arranged trading plan to cover tax withholding on vested equity awards; he retained 5,064 shares, making the transaction less indicative of a change in business outlook. SEC Filing
• Negative Sentiment: RBC’s “sector perform” rating came with a $965 target—below the recent share price—suggesting limited upside in that firm’s view despite its target increase. RBC on McKesson’s Execution

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.